Benefits of Livmarli for cholestasis sustained up to 2 years: Trial data
Up to two years of daily treatment with Livmarli (maralixibat) controlled itch and reduced blood levels of bile acids and bilirubin, two markers of…
News
Acute-on-chronic liver failure in BA linked to transplant complications
Children with biliary atresia who have a serious condition called acute-on-chronic liver failure (ACLF) tend to require a longer stay in the hospital and are…
FDA breakthrough designation granted to larsucosterol for AH
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to larsucosterol, Durect’s investigational therapy for people with severe alcohol-associated hepatitis…
Seladelpar eases liver damage, itch in primary biliary cholangitis
One year of treatment with Gilead Sciences’ seladelpar normalized biomarkers of liver injury and rapidly reduced itch for most people with primary biliary…
Blood scores may help with ICP diagnosis, management: Study
Two scores calculated from blood biomarkers can accurately discriminate between pregnant women with intrahepatic cholestasis of pregnancy (ICP) and those without, and predict ICP-associated…
Namodenoson study for severe fatty liver disease cleared for US
Can-Fite BioPharma has been approved to enroll U.S. patients in its ongoing Phase 2b clinical trial of the oral treatment candidate namodenoson in people…
Rare liver cancer found in toddler with Alagille syndrome
A toddler boy with cirrhosis, or permanent liver scarring, due to Alagille syndrome developed a hepatoblastoma, a type of liver cancer that typically occurs…
Autoimmune hepatitis treatment zetomipzomib trial seeks patients
A Phase 2a clinical trial testing Kezar Life Sciences’ investigational therapy zetomipzomib in adults with autoimmune hepatitis who did not respond well to standard…
Analyses on volixibat trial data in PSC, PBC slated for June
Interim analyses of data from Phase 2 clinical trials testing Mirum Pharmaceuticals’ oral therapy candidate volixibat in people with itch, or pruritus, due to…
Livmarli benefits seen across PFIC types, trial data show
Treatment with Livmarli (maralixibat) leads to significant clinical benefits for people with progressive familial intrahepatic cholestasis (PFIC) across a wide range of disease…
Recent Posts
- Awareness month focuses on challenges for rural communities
- My son’s fourth birthday is yet another milestone to celebrate
- Weight loss surgery may protect liver with MASH-related cirrhosis
- Livmarli relieves itch in adolescents with Alagille syndrome: Analysis
- HBV vaccine birth dose not tied to premature babies’ lung disease risk